Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 3;13(1):240.
doi: 10.1038/s41398-023-02537-9.

Network effects of Stanford Neuromodulation Therapy (SNT) in treatment-resistant major depressive disorder: a randomized, controlled trial

Affiliations
Randomized Controlled Trial

Network effects of Stanford Neuromodulation Therapy (SNT) in treatment-resistant major depressive disorder: a randomized, controlled trial

Jean-Marie Batail et al. Transl Psychiatry. .

Abstract

Here, we investigated the brain functional connectivity (FC) changes following a novel accelerated theta burst stimulation protocol known as Stanford Neuromodulation Therapy (SNT) which demonstrated significant antidepressant efficacy in treatment-resistant depression (TRD). In a sample of 24 patients (12 active and 12 sham), active stimulation was associated with significant pre- and post-treatment modulation of three FC pairs, involving the default mode network (DMN), amygdala, salience network (SN) and striatum. The most robust finding was the SNT effect on amygdala-DMN FC (group*time interaction F(1,22) = 14.89, p < 0.001). This FC change correlated with improvement in depressive symptoms (rho (Spearman) = -0.45, df = 22, p = 0.026). The post-treatment FC pattern showed a change in the direction of the healthy control group and was sustained at the one-month follow-up. These results are consistent with amygdala-DMN connectivity dysfunction as an underlying mechanism of TRD and bring us closer to the goal of developing imaging biomarkers for TMS treatment optimization.Trial registration: ClinicalTrials.gov NCT03068715.

PubMed Disclaimer

Conflict of interest statement

Dr. Williams is a named inventor on Stanford-owned intellectual property relating to accelerated TMS pulse pattern sequences and neuroimaging-based TMS targeting; he has served on scientific advisory boards for Otsuka, NeuraWell, Magnus Medical, and Nooma as a paid advisor; and he has equity/stock options in Magnus Medical, NeuraWell, and Nooma. All other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1. Glass brain visualization of the three FC pairs that survived Bonferroni correction (Table 1).
Networks name: AMY: amygdala, DMN: default mode network, SN: salience network, STR: striatum. The thickness of each connecting edge is representative of the F-statistic, strength of connection, between corresponding seeds.
Fig. 2
Fig. 2. Grids summarizing the three FC pairs that demonstrated the strongest group*time interaction, relationship between FC and clinical changes or trend to normalization to HC FC level (Bonferroni corrected).
A LH AMY S—LH DMN PFC3, B RH AMY S—LH SN Med3, C RH STR sensorimotor—RH SN FrOperIns1. Panels 1: group*time interaction plot from baseline to immediate-post; Panels 2: Correlation between MADRS changes and FC changes from baseline to immediate-post; Panels 3: barplot illustrating mean FC z-score post-hoc comparisons between group FC across three timepoints and healthy control group; Panels 4: glass brain visualization of the corresponding FC pair. LH: left hemisphere, RH: right hemisphere. Networks name: AMY (red nodes): amygdala, DMN (yellow nodes): default mode network, SN (light blue nodes): salience network, STR (green nodes): striatum. The thickness of each connecting edge is representative of the F-statistic, strength of connection, between corresponding seeds. FC: functional connectivity; HC: healthy control group. ****p ≤ 0.001, *p ≤ 0.05.

Similar articles

Cited by

References

    1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL, et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010. PLoS Med. 2013;10:e1001547. - PMC - PubMed
    1. Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry [Internet] 2021;82:20m13699. - PubMed
    1. Williams LM. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016;3:472–80. doi: 10.1016/S2215-0366(15)00579-9. - DOI - PMC - PubMed
    1. Etkin A, Büchel C, Gross JJ. The neural bases of emotion regulation. Nat Rev Neurosci. 2015;16:693–700. doi: 10.1038/nrn4044. - DOI - PubMed
    1. Chen AC, Oathes DJ, Chang C, Bradley T, Zhou ZW, Williams LM, et al. Causal interactions between fronto-parietal central executive and default-mode networks in humans. Proc Natl Acad Sci USA. 2013;110:19944–9. doi: 10.1073/pnas.1311772110. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data